tiprankstipranks
Advertisement
Advertisement

NRSN Stock Latest News

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
Company AnnouncementsNeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
5d ago
6K
NRSN
NeuroSense announces departure of Chief Medical Officer
PremiumThe Fly
NeuroSense announces departure of Chief Medical Officer
7d ago
NRSN
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones
PremiumCompany Announcements
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones
9d ago
6K
NRSN
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC
PremiumCompany Announcements
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC
27d ago
6K
NRSN
NeuroSense granted Brazilian patent covering PrimeC composition
PremiumThe Fly
NeuroSense granted Brazilian patent covering PrimeC composition
27d ago
NRSN
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status
PremiumCompany AnnouncementsNeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status
30d ago
6K
NRSN
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial
Premium
Company Announcements
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial
1M ago
6K
NRSN
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens
Premium
Company Announcements
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens
1M ago
6K
NRSN
Neurosense Therapeutics Ltd. (NRSN) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Neurosense Therapeutics Ltd. (NRSN) Q4 Earnings Cheat Sheet
1M ago
NRSN
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology
PremiumCompany Announcements
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology
2M ago
6K
NRSN
NeuroSense Shareholders Approve Increase in Registered Share Capital
PremiumCompany Announcements
NeuroSense Shareholders Approve Increase in Registered Share Capital
2M ago
6K
NRSN
NeuroSense initiated with a Buy at Roth Capital
PremiumThe Fly
NeuroSense initiated with a Buy at Roth Capital
2M ago
NRSN
NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial
PremiumCompany AnnouncementsNeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial
2M ago
6K
NRSN
NeuroSense reports additional long-term survival data from PARADIGM 2b trial
Premium
The Fly
NeuroSense reports additional long-term survival data from PARADIGM 2b trial
2M ago
NRSN
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase
Premium
Company Announcements
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase
3M ago
6K
NRSN
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042
PremiumCompany Announcements
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042
3M ago
6K
NRSN
NeuroSense granted Australian patent covering PrimeC composition
PremiumThe Fly
NeuroSense granted Australian patent covering PrimeC composition
3M ago
NRSN
NeuroSense files $150M mixed securities shelf
PremiumThe Fly
NeuroSense files $150M mixed securities shelf
3M ago
NRSN
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash
PremiumCompany Announcements
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash
4M ago
6K
NRSN
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial
PremiumCompany AnnouncementsNeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial
4M ago
6K
NRSN
NeuroSense confirms favorable safety, tolerability of Prime C in Phase 2 study
Premium
The Fly
NeuroSense confirms favorable safety, tolerability of Prime C in Phase 2 study
4M ago
NRSN
NeuroSense Completes Data Collection for Alzheimer’s Trial
Premium
Company Announcements
NeuroSense Completes Data Collection for Alzheimer’s Trial
5M ago
6K
NRSN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >